median age at onset of 28 years. However, in young patients secondary causes of dementia are quite frequent, most of which are due to various forms of autoimmune inflammatory brain disorders or vasculitis. This subgroup of patients suffers from potentially treatable disorders, thus a detailed examination and a variety of tests from laboratory work-up and brain imaging up to brain biopsy 4 should be performed.
Alzheimer's-type Dementia
In 1906, Alois Alzheimer was the first to describe in detail the symptoms and pathological changes in his patient Auguste D. Auguste D suffered from a pre-senile form of dementia, being 51 years of age at disease onset. In 1911, Emil Kraepelin introduced Alzheimer's dementia for the first time into the scientific literature. The term was used to describe pre-senile dementia for many years. Only in later years was the term Alzheimer's dementia extended to include senile dementias of a primary degenerative nature with similar neuropathological changes. Alzheimer's dementia is characterised by progressive cognitive impairment and prolonged disease duration (seven years on average). Alzheimer's disease is the most frequent cause of dementia. 5 In most cases, the progression of the disease is slow, with disease duration of approximately 10 years, although rapid progression is observed in some cases. Early occurrence of focal signs has been reported to indicate poor prognosis. [6] [7] [8] [9] Motor signs and their frequency in Alzheimer's disease patients have previously been reported. [10] [11] [12] [13] The frequency increases during the course of the disease. Tremor is observed in 11% of the Alzheimer's disease population, rigidity in 26% and posture instability/gait disturbance/falls in 29%. 12 Occurrence of motor signs seems to be predictive of a poor outcome in Alzheimer's disease. 9 Early-onset Alzheimer's disease shows a more rapid progression, more generalised cognitive deficits and greater cortical atrophy and hypometabolism compared with late-onset patients at a similar disease stage. 14, 15 Furthermore, atrophy in early-onset Alzheimer's disease is localised predominantly occipital Neurodegenerative Disease Dementia Differential Diagnosis of Rapid Progressive Dementia in whom chromosome 21 is present in triplicate, are at an increased risk of Alzheimer's disease. The clinical presentation is similar to that of sporadic AD, apart from age at onset, but some mutations can present with characteristic clinical features such as early behavioural change, 18 speech production deficit 19 or spastic paraparesis with white-matter changes. 20 In addition, the apolipoprotein E (ApoE) polymorphism on chromosome 19 has been identified as a risk factor.
There are three alleles of ApoE (2, 3 and 4), and about two-thirds of the general population has the ApoE3 form of the gene. However, ApoE4 is known to be a relative and gene-dosage-dependent risk factor for AD.
Lewy Body Dementia
In contrast to other neurodegenerative dementias, pre-senile onset of LBD is very rare, comprising only 4% of early-onset dementias. LBD is Recently, some antibodies have been reported. 22 Correct diagnosis is important as neuroleptics are obsolete in LBD, causing marked reduction of vigilance.
Vascular Dementias
There is agreement in the literature that dementia can be caused by cerebrovascular diseases. However, the most common concepts and classifications are heterogeneous. In general, a distinction is made between macroangiopathy and microangiopathy, cortical and subcortical multi-infarct dementia and dementia due to Ubiquitin-positive cellular inclusions, which are typical of motor neuron diseases, are also found.
Pre-senile Dementia
The underlying cause of pre-senile dementia spans a wide range, with a higher frequency of familial, autoimmune and metabolic reasons.
Furthermore, toxic exposure plays a more important role in the differential diagnosis than in older people. A list of mutations associated with dementia is given in Table 3 . A typical pre-senile neurodegenerative disorder is Huntington's disease, which is caused by autosomal-dominant expansion of CAG trinucleotide repeats in the
huntingtin gene on chromosome 4. The prevalence in Europe is up to 8/100,000. The cognitive decline starts typically in middle age with neuropsychiatric symptoms, followed by subcortical dementia and extrapyramidal signs such as choreatiform hyperkinesias. In addition to familial disorders, a higher frequency of metabolic disorders is ascertained in the differential diagnosis of pre-senile dementia.
Mitochondrial disorders (incidence 2/10,000), Wilson's disease (incidence 1/30,000-300,000) and lysosomal storage diseases such as Fabry's disease or Niemann-Pick type C (incidence 1/8,000) are examples of this entity, some of which have known causative mutations. Usually, metabolic disorders cause a subcortical dementia characterised by disturbance of vigilance and attention; memory Differential Diagnosis of Rapid Progressive Dementia Furthermore, it inhibits neurogenesis from progenitor neuronal cells in the brain. 27 The standard for HIV therapy, highly active antiretroviral therapy (HAART), has reduced the incidence in favour of increasing prevalence. It has also been shown that HAART can delay the onset of dementia and even improve already existing ADC. Recently, ADC patients treated with memantine showed neuropsychological improvement. 28 Chronic abuse of alcohol can result in multiple cognitive changes. The well-known Wernicke-Korsakow syndrome is characterised by amnestic disturbances associated with other neurological problems (polyneuropathy, oculomotor signs, ataxia and vegetative symptoms).
It is believed to be caused by malnutrition, especially thiamine deficiency. Thus, therapy demands early substitution of thiamine.
Nevertheless, clinical improvement is uncommon due to advanced changes in brain. Additionally, a primary alcohol dementia due to direct neurotoxic effects has been described, but seems to be rare. 29 It typically presents as combined frontal and subcortical dementia. It has been shown that symptoms stabilise or even improve after several months of strict alcohol abstinence.
Potentially Reversible Dementias
Dementia syndromes may have a neurodegenerative aetiology, but they can also be caused by potentially reversible diseases. The percentage of potentially reversible dementias, according to investigations, is 10% of all cases in memory clinics. This proportion is even higher (about one-third) among patients with rapidly progressive dementia. Diagnosis is made by intestinal biopsy and detection of PAS-positive macrophage inclusions, which can also be found in the CSF.
Furthermore, antibodies can be detected. As this is a bacterial infection, therapy is based on antibiotic therapy for at least one year.
Cerebrospinal Fluid Tests
The CSF is the main component of the brain's extracellular space and participates in the exchange of many biochemical products in the CNS. Consequently, CSF contains a dynamic and complex mixture of proteins that reflects the physiological or pathological state of the CNS. 31 CSF analysis is extremely important for the identification of autoimmune disorders and inflammatory conditions that might lead normal levels 44 or even significantly reduced level 45 were observed in others. A potential explanation for this might be the heterogeneity of the definitions of frontotemporal dementia used. Conflicting data are available also for LBD, with either increased 46 or normal [47] [48] [49] concentrations compared with non-demented groups. Significantly decreased tau concentrations in LBD patients compared with
Alzheimer's disease have also occasionally been reported. 50, 51 One study described that the total tau level in CSF from NPH patients was significantly higher than that in controls, with a correlation between tau levels and dementia or urinary incontinence. 52 Our own data demonstrated increased tau protein concentrations in CJD, Alzheimer's disease, LBD and frontotemporal dementia, but not in NPH, while only patients with CJD dissociated significantly from the other dementias. 40 To summarise, these markers have become standard CSF tests in the routine dementia work-up. Although some data point towards a limited value of these markers in the clinical differential diagnosis between dementia entities, their specificity can be increased if they are used in a defined clinical context. Their value is high when they are used as a part of a multimodal approach together with neuropsychological test batteries and brain imaging. In addition, the determination of ratios and isoforms is helpful. The ratio calculated from the pathological Aβ and from the less aggregating form Aβ 1-40 is of considerable value in the diagnosis of Alzheimer's disease: it has been found that ratios <1.0 are indicative of Alzheimer's disease. With respect to tau, its phosphorylated form at T181 has been identified as indicating hyperphosphorylation, and it is thus considered to be a disease-specific marker for Alzheimer's disease. The ratio calculated from tau protein phosphorylated at T181
and total tau has also increased its diagnostic utility.
Recent studies on the value of tau and Aβ as potential markers for differentiation of AD from other dementias have also shown that similar results might be obtained for other dementias, too. Thus, due to their non-specificity and low discrimination levels between different neurodegenerative dementia types, the search for a CSF (or blood) biomarker is still ongoing.
Summary
The clinical symptom dementia is characterised by a variety of changes in memory, planning, orientation and processing speed. 
